Edition:
United Kingdom

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

14.55USD
20 Apr 2018
Change (% chg)

$-0.20 (-1.36%)
Prev Close
$14.75
Open
$14.75
Day's High
$14.80
Day's Low
$14.50
Volume
54,724
Avg. Vol
78,970
52-wk High
$16.40
52-wk Low
$13.25

Chart for

About

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $620.38
Shares Outstanding(Mil.): 42.20
Dividend: 0.12
Yield (%): 3.40

Financials

  VIVO.OQ Industry Sector
P/E (TTM): 29.32 32.19 32.74
EPS (TTM): 0.50 -- --
ROI: 9.27 13.89 14.38
ROE: 12.68 16.72 16.07

BRIEF-Meridian Bioscience Reports Q1 GAAP EPS Of $0.15

* MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER 2018 OPERATING RESULTS, DECLARES REGULAR FIRST QUARTER CASH DIVIDEND, AND REAFFIRMS FISCAL 2018 GUIDANCE

25 Jan 2018

BRIEF-Co-Diagnostics Announces Sale Of Molecular Diagnostic Tests

* CO-DIAGNOSTICS, INC. ANNOUNCES SALE OF MOLECULAR DIAGNOSTIC TESTS, INCLUDING ZIKA VIRUS, TO MAJOR CARIBBEAN LABORATORY Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Meridian Bioscience Files For Mixed Shelf Of Up To $100 Million

* MERIDIAN BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: (http://bit.ly/2k7rdVf) Further company coverage:

29 Nov 2017

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

15 Nov 2017

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

24 Oct 2017

CORRECTED-UPDATE 2-FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

24 Oct 2017

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - ‍announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary​

23 Oct 2017

FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

23 Oct 2017

Competitors

Earnings vs. Estimates